Sat, Aug 23, 2014, 9:09 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Elite Pharmaceuticals, Inc. Message Board

  • mello137 mello137 Mar 17, 2014 9:38 AM Flag

    I'll do my own DD.. But I would like some input

    I’m just looking for some clarification on Elite and its ART products. I’m new to elite and to this forum. But I was doing a little DD and I came across some articles and information that I would like for this forum to help me clarify. Doing a simple Google search, I was found and article that mentioned a product that used a similar technique as elite called Embeda. Does elite add another process to the mix? I hope this isn't a long read.

    “Another entry into the abuse-proof market, an agonist-antagonist, is the morphine sulfate-naltrexone combo marketed as Embeda. The antagonist naltrexone -- which blocks opioid receptors -- remains latent if the drug is taken as prescribed, but can reduce the effects of the morphine, or even lead to withdrawal, if crushed. But Embeda was recently pulled from the market because of stability problems and will likely remain unavailable for many months, according to reports.”

    And another article mentions this about Embeda; “Nor did Alpharma's registration studies establish whether naltrexone's reduction of morphine effects following chewing or crushing was clinically significant. The product's label cautions that there is no evidence that Embeda is less likely to be abused than other extended-release morphine drugs.
    In fact, it carries this warning: "Embeda can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing Embeda in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion."

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ELTP.OB
0.00(0.00%)

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.